These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 30082419)

  • 1. Adult
    Rotaru DC; van Woerden GM; Wallaard I; Elgersma Y
    J Neurosci; 2018 Sep; 38(37):8011-8030. PubMed ID: 30082419
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Wallace ML; van Woerden GM; Elgersma Y; Smith SL; Philpot BD
    J Neurophysiol; 2017 Jul; 118(1):634-646. PubMed ID: 28468997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the requirements of prenatal UBE3A expression for rescue of behavioral phenotypes in a mouse model for Angelman syndrome.
    Sonzogni M; Zhai P; Mientjes EJ; van Woerden GM; Elgersma Y
    Mol Autism; 2020 Sep; 11(1):70. PubMed ID: 32948244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Operant Extinction and Prefrontal Excitability in a Mouse Model of Angelman Syndrome.
    Sidorov MS; Judson MC; Kim H; Rougie M; Ferrer AI; Nikolova VD; Riddick NV; Moy SS; Philpot BD
    J Neurosci; 2018 Mar; 38(11):2671-2682. PubMed ID: 29431654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.
    Silva-Santos S; van Woerden GM; Bruinsma CF; Mientjes E; Jolfaei MA; Distel B; Kushner SA; Elgersma Y
    J Clin Invest; 2015 May; 125(5):2069-76. PubMed ID: 25866966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angelman Syndrome: From Mouse Models to Therapy.
    Rotaru DC; Mientjes EJ; Elgersma Y
    Neuroscience; 2020 Oct; 445():172-189. PubMed ID: 32088294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal Loss of Ube3a Impairs Experience-Driven Dendritic Spine Maintenance in the Developing Visual Cortex.
    Kim H; Kunz PA; Mooney R; Philpot BD; Smith SL
    J Neurosci; 2016 Apr; 36(17):4888-94. PubMed ID: 27122043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UBE3A expression during early postnatal brain development is required for proper dorsomedial striatal maturation.
    Rotaru DC; Wallaard I; de Vries M; van der Bie J; Elgersma Y
    JCI Insight; 2023 Feb; 8(4):. PubMed ID: 36810252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed loss of UBE3A reduces the expression of Angelman syndrome-associated phenotypes.
    Sonzogni M; Hakonen J; Bernabé Kleijn M; Silva-Santos S; Judson MC; Philpot BD; van Woerden GM; Elgersma Y
    Mol Autism; 2019; 10():23. PubMed ID: 31143434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of dopaminergic neurons and resulting behavioural deficits in mouse model of Angelman syndrome.
    Mulherkar SA; Jana NR
    Neurobiol Dis; 2010 Dec; 40(3):586-92. PubMed ID: 20696245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards an understanding of Angelman syndrome in mice studies.
    Yang X
    J Neurosci Res; 2020 Jun; 98(6):1162-1173. PubMed ID: 31867793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity-dependent changes in MAPK activation in the Angelman Syndrome mouse model.
    Filonova I; Trotter JH; Banko JL; Weeber EJ
    Learn Mem; 2014 Jan; 21(2):98-104. PubMed ID: 24434871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome.
    Elgersma Y; Sonzogni M
    Dev Med Child Neurol; 2021 Jul; 63(7):802-807. PubMed ID: 33543479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JNK signaling activation in the Ube3a maternal deficient mouse model: its specific inhibition prevents post-synaptic protein-enriched fraction alterations and cognitive deficits in Angelman Syndrome model.
    Musi CA; Agrò G; Buccarello L; Camuso S; Borsello T
    Neurobiol Dis; 2020 Jul; 140():104812. PubMed ID: 32087286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Nociception in Angelman Syndrome Model Mice.
    McCoy ES; Taylor-Blake B; Aita M; Simon JM; Philpot BD; Zylka MJ
    J Neurosci; 2017 Oct; 37(42):10230-10239. PubMed ID: 28931574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a Novel Rat Model of Angelman Syndrome with a Complete Ube3a Gene Deletion.
    Dodge A; Peters MM; Greene HE; Dietrick C; Botelho R; Chung D; Willman J; Nenninger AW; Ciarlone S; Kamath SG; Houdek P; Sumová A; Anderson AE; Dindot SV; Berg EL; O'Geen H; Segal DJ; Silverman JL; Weeber EJ; Nash KR
    Autism Res; 2020 Mar; 13(3):397-409. PubMed ID: 31961493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model.
    Milazzo C; Mientjes EJ; Wallaard I; Rasmussen SV; Erichsen KD; Kakunuri T; van der Sman ASE; Kremer T; Miller MT; Hoener MC; Elgersma Y
    JCI Insight; 2021 Aug; 6(15):. PubMed ID: 34369389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal electrophysiological phenotypes and sleep deficits in a mouse model of Angelman Syndrome.
    Copping NA; Silverman JL
    Mol Autism; 2021 Feb; 12(1):9. PubMed ID: 33549123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imprinting effects of UBE3A loss on synaptic gene networks and Wnt signaling pathways.
    Lopez SJ; Laufer BI; Beitnere U; Berg EL; Silverman JL; O'Geen H; Segal DJ; LaSalle JM
    Hum Mol Genet; 2019 Nov; 28(22):3842-3852. PubMed ID: 31625566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward a Broader View of Ube3a in a Mouse Model of Angelman Syndrome: Expression in Brain, Spinal Cord, Sciatic Nerve and Glial Cells.
    Grier MD; Carson RP; Lagrange AH
    PLoS One; 2015; 10(4):e0124649. PubMed ID: 25894543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.